INTRODUCTION
============

Overall survival (OS) for women with metastatic breast cancer (MBC) has improved over recent decades. Long-term survival, however, remains poor,^[@B1],[@B2]^ highlighting the unmet need for therapy that is effective, improves quality of life (QoL), and prolongs survival.

Anthracycline- or taxane-based regimens are commonly used in the treatment of breast cancer, often in the (neo)adjuvant and first-line metastatic settings.^[@B3]^ However, treatment decisions in subsequent lines are increasingly difficult.^[@B4]^ There is no single accepted standard of care after failure of anthracycline and taxane therapy^[@B5]^; capecitabine is commonly used in the first-, second-, and third-line settings for MBC. Capecitabine has also been the control arm in several phase III trials in MBC.^[@B6]--[@B9]^

Eribulin mesylate (International Nonproprietary Name is eribulin) is a nontaxane microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents.^[@B10],[@B11]^ It has a mechanism of action distinct from other tubulin-targeted agents, binding predominantly to a small number of high-affinity sites on the growing plus ends of microtubules.^[@B10]--[@B14]^ Such highly focused end-binding may decrease the likelihood of effects from eribulin on normal physiologic microtubule functions in nonmalignant cells.^[@B15],[@B16]^ In contrast to most other tubulin-targeted agents, mitotic blockade with eribulin is irreversible, and intermittent drug exposure leads to long-term loss of cell viability.^[@B17]^

The first phase III trial of eribulin (Eisai Metastatic Breast Cancer Study Assessing Physician\'s Choice Versus Eribulin \[EMBRACE\]) compared eribulin with treatment of physician\'s choice (TPC) in patients with MBC who had received at least two prior chemotherapy regimens for advanced disease but no more than five cytotoxic regimens in total. In this trial, there was a significant improvement in OS for eribulin compared with TPC; this was confirmed in the updated analysis requested by European and US regulatory authorities. The median OS was 13.2 months for eribulin versus 10.5 months for TPC (hazard ratio \[HR\], 0.81; 95% CI, 0.67 to 0.96; nominal \[analysis not prespecified\] *P* = .01). Furthermore, eribulin had a manageable safety profile, with the most common adverse events (AEs) being asthenia or fatigue, and neutropenia.^[@B18],[@B19]^

As a result, eribulin has been approved in more than 50 countries as monotherapy for patients with advanced breast cancer or MBC who have previously received at least two chemotherapeutic regimens for advanced/metastatic disease, with prior therapy having included an anthracycline and a taxane in the adjuvant or metastatic setting.^[@B20]^ We report results from a second phase III study comparing eribulin with capecitabine as first-, second-, or third-line therapy for advanced breast cancer or MBC. Detailed QoL and pharmacokinetic/pharmacodynamic results will be reported separately.

PATIENTS AND METHODS
====================

Patients
--------

Inclusion criteria included: female sex; age ≥ 18 years; histologically or cytologically confirmed breast cancer; up to three prior chemotherapy regimens and up to two prior chemotherapy regimens for advanced and/or metastatic disease; prior therapy with an anthracycline and a taxane; resolution of all chemotherapy- or radiation-related toxicities to ≤ grade 1 (except for stable sensory neuropathy ≤ grade 2 and alopecia); Eastern Cooperative Oncology Group performance status of 0 to 2; and adequate renal, bone marrow, and liver function. Measurable or nonmeasurable disease was allowed. Exclusion criteria included prior capecitabine treatment and radiation therapy encompassing more than 30% of marrow. Patients with human epidermal growth factor receptor 2 (HER2) --positive disease could have received HER2-targeted therapy before or after study treatment but not while on study treatment.

All patients provided written informed consent. Approval was obtained from independent ethics committees and regulatory authorities in participating countries. The study was conducted in accordance with the World Medical Association Declaration of Helsinki, guidelines of the International Conference for Harmonisation/Good Clinical Practice, and local ethical and legal requirements.

Study Design
------------

This phase III, open-label, parallel, two-arm, multicenter trial (study No. E7389-G000-301; ClinicalTrials.gov identifier: NCT00337103) stratified patients by geographic region (Latin America, Western Europe/Australia, Eastern Europe, North America, Asia, or South Africa) and the HER2 status of their cancer (positive, negative, or unknown). Patients were randomly assigned (1:1) using a central interactive voice-response system to receive eribulin mesylate 1.4 mg/m^2^ (equivalent to eribulin 1.23 mg/m^2^ \[expressed as free base\]) intravenously over 2 to 5 minutes on days 1 and 8, or capecitabine 1.25 g/m^2^ orally twice per day on days 1 to 14, both in 21-day cycles. Patients received study treatment until disease progression, unacceptable toxicity, or patient/investigator request to discontinue. Grade 3 and 4 toxicities and certain grade 2 toxicities for capecitabine were managed by treatment interruption and/or dose reduction and symptomatic treatment. Use of colony-stimulating factors and erythropoietin was allowed according to American Society of Clinical Oncology guidelines or local practice.

Study Objectives
----------------

Coprimary end points, as used in other clinical trials,^[@B21]^ were OS and progression-free survival (PFS). Secondary end points included objective response rate (ORR); duration of response; 1-, 2-, and 3-year survival; safety; QoL; and population pharmacokinetic/pharmacodynamic relationships.

Study Assessments
-----------------

OS was measured from date of random assignment until date of death from any cause or last date known alive/data cutoff (censored). PFS was measured from date of random assignment to date of recorded disease progression or death from any cause.

Tumor response was determined according to RECIST (version 1.0), censored at last tumor assessment before subsequent anticancer therapy or before two or more missed scheduled tumor assessments,^[@B22]^ and confirmed by a second assessment at least 4 weeks after first observation of response. An independent radiology review was performed; in a protocol amendment requested by the US Food and Drug Administration, a bone scan was required to confirm tumor response. Duration of response was defined as the time from first documented complete or partial response until disease progression, death from any cause, or censoring at date of last tumor assessment. AEs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3).

QoL Analyses
------------

QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (version 3.0) and breast module Quality of Life Questionnaire BR23 (version 1.0) at baseline, at 6 weeks, and at 3, 6, 12, 18, and 24 months or until disease progression or initiation of other antitumor treatment. The principal prespecified outcome was overall QoL, expressed as change from baseline in Global Health Status (GHS)/QoL measured on a 0 (worst) to 100 (best) scale.

Statistical Analyses
--------------------

Because there were coprimary end points, the total type I error was split, 0.04 for OS and 0.01 for PFS. Sample size was based on a superiority test of OS; when 905 events (deaths) were observed, the two-sided log-rank test had 90% power to detect a 3-month increase in median survival over a 12-month median survival for capecitabine (HR, 0.80). Planned enrollment was 1,100 patients with a maximum of 55 patients per study site.

Primary efficacy analysis used the intent-to-treat population comprising all randomly assigned patients. The safety population included all patients who received at least one dose of treatment. Tumor assessments were obtained from an independent radiology review (primary analysis) and an investigator radiology review (secondary analysis).

The coprimary end points, OS and PFS, were compared between treatment groups using two-sided, stratified (geographic region and HER2 status) log-rank tests. Interim planned OS analyses were performed after 453 and 603 deaths. To maintain an overall level of 0.04, α spending for sequential analyses of OS was based on Lan-DeMets implementation of the O\'Brien-Fleming spending function^[@B23]^; the nominal significance levels of the first and second interim analyses and final analysis were *P* = .002, *P* = .0081, and *P* = .0372, respectively. The study would be defined as positive if, at final analysis, either OS with eribulin was statistically significantly better (*P* ≤ .0372) versus capecitabine or PFS with eribulin was statistically significantly better (*P* ≤ .01) versus capecitabine, and the HR for OS (eribulin/capecitabine) was less than 1. ORRs were compared between treatment groups using Fisher\'s exact test. As prespecified in the statistical analyses plan, exploratory analyses of OS and PFS by the stratification factors of HER2 status and geographic region were also performed.

For the principal QoL outcome, longitudinal analyses were carried out using linear mixed model and pattern-mixture model techniques. An independent data monitoring committee reviewed safety and efficacy data from interim analyses. The sponsor (Eisai, Woodcliff Lake, NJ) collected and analyzed all data with the exception of the QoL analyses, which were conducted by Clinical Outcomes Solutions (Evergreen, CO).

RESULTS
=======

Patients
--------

From September 2006 to September 2009, 1,102 patients were randomly assigned, 554 to eribulin and 548 to capecitabine ([Fig 1](#F1){ref-type="fig"}). Baseline patient demographics and disease characteristics were generally well balanced ([Table 1](#T1){ref-type="table"}); there were small differences in the percentages of patients who had estrogen receptor--positive and triple-negative disease (46.8% *v* 50.7%, and 27.1% *v* 24.5% for eribulin and capecitabine, respectively). Overall, 68.5% of patients had HER2-negative disease. Twenty percent, 52.0%, and 27.2% of patients received study therapy as first-line, second-line, and third-line treatment, respectively, for advanced disease.

![CONSORT diagram.](zlj9991050110001){#F1}

###### 

Patient Demographic and Baseline Clinical Characteristics (intent-to-treat population)
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  Characteristic                                                   Eribulin (n = 554)   Capecitabine (n = 548)         
  ---------------------------------------------------------------- -------------------- ------------------------ ----- ------
  Age, years                                                                                                           
      Median                                                       54.0                 53.0                           
      Range                                                        24-80                26-80                          
  Race                                                                                                                 
      White                                                        496                  89.5                     495   90.3
      Asian/Pacific Islander                                       18                   3.2                      18    3.3
      Black or African American                                    15                   2.7                      16    2.9
      Other                                                        25                   4.5                      19    3.5
  Geographic region                                                                                                    
      Eastern Europe                                               307                  55.4                     305   55.7
      Latin America                                                105                  19.0                     104   19.0
      Western Europe                                               80                   14.4                     77    14.1
      North America                                                44                   7.9                      43    7.8
      Asia                                                         13                   2.3                      12    2.2
      South Africa                                                 5                    0.9                      7     1.3
  ECOG performance status                                                                                              
      0                                                            250                  45.1                     230   42.0
      1                                                            293                  52.9                     301   54.9
      2                                                            11                   2.0                      16    2.9
      3                                                            0                    0                        1     0.2
  No. of prior chemotherapy regimens                                                                                   
      0                                                            1                    0.2                      0     0
      1                                                            147                  26.5                     153   27.9
      2                                                            319                  57.6                     314   57.3
      3                                                            84                   15.2                     78    14.2
      4                                                            3                    0.5                      2     0.4
      5                                                            0                    0                        1     0.2
  No. of prior chemotherapy regimens for advanced disease                                                              
      0                                                            116                  20.9                     104   19.0
      1                                                            280                  50.5                     293   53.5
      2                                                            154                  27.8                     146   26.6
      \> 2                                                         4                    0.7                      5     0.9
  Refractory to treatment with:[\*](#TF1-1){ref-type="table-fn"}                                                       
      Taxane                                                       250                  45.1                     260   47.4
      Anthracycline                                                134                  24.2                     139   25.4
      Taxane and anthracycline                                     91                   16.4                     103   18.8
  HER2 status                                                                                                          
      Positive                                                     86                   15.5                     83    15.1
      Negative                                                     375                  67.7                     380   69.3
      Not done                                                     93                   16.8                     85    15.5
  ER status                                                                                                            
      Positive                                                     259                  46.8                     278   50.7
      Negative                                                     233                  42.1                     216   39.4
      Not done                                                     62                   11.2                     54    9.9
  PgR status                                                                                                           
      Positive                                                     227                  41.0                     234   42.7
      Negative                                                     262                  47.3                     248   45.3
      Not done                                                     65                   11.7                     66    12.0
  Triple (HER2/ER/PgR) negative                                    150                  27.1                     134   24.5
  Most common metastatic sites[†](#TF1-2){ref-type="table-fn"}                                                         
      Bone                                                         299                  54.0                     308   56.2
      Lung                                                         279                  50.4                     280   51.1
      Lymph nodes                                                  268                  48.4                     274   50.0
      Liver                                                        247                  44.6                     271   49.5
  No. of organs involved                                                                                               
      1                                                            113                  20.4                     92    16.8
      2                                                            174                  31.4                     177   32.3
      3                                                            153                  27.6                     149   27.2
      ≥ 4                                                          114                  20.6                     129   23.5
      Missing                                                      0                    0                        1     0.2
  Site of disease[‡](#TF1-3){ref-type="table-fn"}                                                                      
      Visceral                                                     467                  84.3                     483   88.1
      Nonvisceral only                                             81                   14.6                     61    11.1
      Missing                                                      6                    1.1                      4     0.7

Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.

Refractory was defined as progression within 60 days after taking the last dose.

Reported by at least 20% of the total population.

Visceral/nonvisceral was determined by independent assessment.

Efficacy
--------

Median OS was 15.9 months (95% CI, 15.2 to 17.6 months) for eribulin compared with 14.5 months (95% CI, 13.1 to 16.0 months) for capecitabine ([Fig 2](#F2){ref-type="fig"}A), resulting in an HR of 0.88 (95% CI, 0.77 to 1.00; *P* = .056). Median PFS was 4.1 months (95% CI, 3.5 to 4.3 months) for eribulin and 4.2 months (95% CI, 3.9 to 4.8 months) for capecitabine (HR, 1.08; 95% CI, 0.93 to 1.25; *P* = .30; [Fig 2](#F2){ref-type="fig"}B). By investigator review, median PFS times were 4.2 months (95% CI, 3.9 to 4.3 months) and 4.1 months (95% CI, 3.7 to 4.5 months) for eribulin and capecitabine, respectively (HR, 0.98; 95% CI, 0.86 to 1.11; *P* = .74).

![Kaplan-Meier curve for (A) overall survival and (B) progression-free survival (independent review; intent-to-treat population). HR, hazard ratio. One-, 2-, and 3-year survival rates were 64.4% and 58.0% (*P* = .04), 32.8% and 29.8% (*P* = .32), and 17.8% and 14.5% (*P* = .18) for eribulin and capecitabine, respectively.](zlj9991050110002){#F2}

ORRs by independent review were 11.0% (95% CI, 8.5% to 13.9%) and 11.5% (95% CI, 8.9% to 14.5%; *P* = .85) for eribulin and capecitabine, respectively ([Table 2](#T2){ref-type="table"}). ORRs by investigator review were 16.1% (95% CI, 13.1% to 19.4%) and 19.9% (95% CI, 16.6% to 23.5%; *P* = .10) for eribulin and capecitabine, respectively.

###### 

Best Overall Tumor Response As Assessed by Independent and Investigator Review (intent-to-treat population)
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  Response                                                  Independent Review   Investigator Review                  
  --------------------------------------------------------- -------------------- --------------------- -------------- --------------
  Tumor response                                                                                                      
      CR                                                                                                              
          No. of patients                                   1                    0                     4              10
          %                                                 0.2                  0                     0.7            1.8
      PR                                                                                                              
          No. of patients                                   60                   63                    85             99
          %                                                 10.8                 11.5                  15.3           18.1
      Stable disease                                                                                                  
          No. of patients                                   313                  303                   332            278
          %                                                 56.5                 55.3                  59.9           50.7
      Progressive disease                                                                                             
          No. of patients                                   125                  133                   99             126
          %                                                 22.6                 24.3                  17.9           23.0
      Not evaluable                                                                                                   
          No. of patients                                   11                   6                     34             35
          %                                                 2.0                  1.1                   6.1            6.4
      Unknown                                                                                                         
          No. of patients                                   44                   43                    0              0
          %                                                 7.9                  7.8                   0              0
      Unconfirmed CR/PR[\*](#TF2-1){ref-type="table-fn"}                                                              
          No. of patients                                   ---                  ---                   21             16
          %                                                                                            3.8            2.9
  Objective response rate[†](#TF2-2){ref-type="table-fn"}                                                             
      No. of patients                                       61                   63                    89             109
      %                                                     11.0                 11.5                  16.1           19.9
      95% CI                                                8.5 to 13.9          8.9 to 14.5           13.1 to 19.4   16.6 to 23.5
      *P*[‡](#TF2-3){ref-type="table-fn"}                   .85                  .10                                  
  Clinical benefit rate[§](#TF2-4){ref-type="table-fn"}                                                               
      No. of patients                                       145                  147                   182            188
      %                                                     26.2                 26.8                  32.9           34.3
      95% CI                                                22.6 to 30.0         23.2 to 30.7          29.0 to 36.9   30.3 to 38.4
      *P*[‡](#TF2-3){ref-type="table-fn"}                   .84                  .61                                  
  Duration of response, months                                                                                        
      Median                                                6.5                  10.8                  6.5            6.7
      95% CI                                                4.9 to 9.0           6.8 to 17.8           4.9 to 7.6     5.8 to 7.9
      *P*[‖](#TF2-5){ref-type="table-fn"}                   .01                  .45                                  

Abbreviations: CR, complete response; PR, partial response.

PR/CR was confirmed as per RECIST in no less than 4 weeks, but bone scan was missing at confirmation visit required by a protocol amendment.

Objective response rate included CR and PR.

Fisher\'s exact test.

Clinical benefit rate was an exploratory end point and included CR, PR, or stable disease of at least 6 months in duration.

Unstratified log-rank test.

### Analyses by stratification factors.

Prespecified exploratory analyses were conducted to assess an effect of eribulin according to HER2 status. Although a possible benefit according to HER2 status was suggested for OS, an interaction test showed no benefit for eribulin when comparing patients with HER2-negative disease and all other patients (HER2-positive and unknown HER2 status).

Safety
------

For eribulin, the median number of treatment cycles was six (range, one to 65 cycles), and the median duration of treatment was 4.1 months (range, 0.7 to 45.1 months). For capecitabine, the median number of treatment cycles was five (range, one to 61 cycles), and the median duration of treatment was 3.9 months (range, 0.7 to 47.4 months). Relative dose-intensity was 87% for eribulin and 86% for capecitabine.

AEs were reported in 94.1% and 90.5% of patients treated with eribulin and capecitabine, respectively. Serious AEs were reported in 17.5% of those receiving eribulin and 21.1% of those receiving capecitabine; these were life-threatening AEs in 2.2% and 3.5% of patients, respectively, and required or prolonged hospitalization in 13.4% and 17.0% of patients, respectively. AEs leading to discontinuation, reduction, or delay in treatment occurred in 7.9%, 32.0%, and 31.8% of patients receiving eribulin and in 10.4%, 31.9%, and 35.7% of those receiving capecitabine, respectively. Fatal AEs (within 30 days of last dose) occurred in 4.8% of patients receiving eribulin and 6.6% of patients receiving capecitabine. These were reported as treatment-related AEs for five patients treated with eribulin (sepsis, pericardial effusion, sudden death, toxic hepatitis, and renal failure) and four patients treated with capecitabine (sepsis, pneumonia, cardiogenic shock, and pancytopenia).

The most common AEs with eribulin were neutropenia, alopecia, leukopenia, global peripheral neuropathy, and nausea. The most common AEs with capecitabine were hand-foot syndrome, diarrhea, and nausea ([Table 3](#T3){ref-type="table"}). Febrile neutropenia occurred at low incidence with both eribulin (2.0%) and capecitabine (0.9%). Most AEs were grade 1 or 2. The most common grade 3 or 4 AEs were neutropenia, leukopenia, asthenia, and global peripheral neuropathy for eribulin, and hand-foot syndrome, diarrhea, neutropenia, dyspnea, and asthenia for capecitabine. Grade 3 or 4 global peripheral neuropathy occurred in 7.0% of patients receiving eribulin and 0.9% of patients receiving capecitabine ([Table 3](#T3){ref-type="table"}). In the eribulin group, the incidences of grade 3 or 4 peripheral motor neuropathy, peripheral sensorimotor neuropathy, and polyneuropathy were 0.7% (all grade 3), 0.6% (all grade 3), and 0.6% (0.4% grade 3, 0.2% grade 4), respectively; these AEs did not occur at grade 3 or 4 in the capecitabine group. The most common AEs leading to discontinuation (occurring in \> 1% of patients) were neutropenia (1.7%) with eribulin and hand-foot syndrome (2.2%) and dyspnea (1.1%) with capecitabine. Colony-stimulating factors were received by 14.6% and 3.6% of patients in the eribulin and capecitabine arms, respectively.

###### 

Most Common Adverse Events (incidence of \> 10% for all grades or \> 2% for ≥ grade 3 in either arm; safety population)
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  Adverse Event                                                       Eribulin (n = 544)   Capecitabine (n = 546)                                                                                         
  ------------------------------------------------------------------- -------------------- ------------------------ ----- ------ ----- ------------------------------------- ----- ------ ---- ------ --- -------------------------------------
  Hematologic                                                                                                                                                                                             
      Neutropenia                                                     295                  54.2                     134   24.6   115   21.1                                  87    15.9   23   4.2    4   0.7
      Leukopenia                                                      171                  31.4                     73    13.4   9     1.7                                   57    10.4   10   1.8    1   0.2
      Anemia                                                          104                  19.1                     11    2.0    0     0                                     96    17.6   5    0.9    1   0.2
      Febrile neutropenia                                             11                   2.0                      8     1.5    3     0.6                                   5     0.9    2    0.4    3   0.5
  Nonhematologic                                                                                                                                                                                          
      Alopecia                                                        188                  34.6                                                                              22    4.0                    
      Global peripheral neuropathy[\*](#TF3-1){ref-type="table-fn"}   149                  27.4                     35    6.4    3     0.6                                   75    13.7   5    0.9    0   0
      Nausea                                                          121                  22.2                     1     0.2    0     0                                     133   24.4   9    1.6    0   0
      Fatigue                                                         91                   16.7                     11    2.0    0     0                                     84    15.4   12   2.2    1   0.2
      Asthenia                                                        83                   15.3                     22    4.0    1     0.2                                   79    14.5   20   3.7    0   0
      Diarrhea                                                        78                   14.3                     6     1.1    0     0                                     157   28.8   28   5.1    1   0.2
      Pyrexia                                                         70                   12.9                     2     0.4    0     0                                     31    5.7    3    0.5    0   0
      Headache                                                        69                   12.7                     4     0.7    0     0                                     57    10.4   2    0.4    1   0.2
      Decreased appetite                                              68                   12.5                     3     0.6    0     0                                     81    14.8   9    1.6    0   0
      Vomiting                                                        65                   11.9                     1     0.2    1     0.2                                   92    16.8   12   2.2    0   0
      Dyspnea                                                         56                   10.3                     10    1.8    2     0.4[†](#TF3-2){ref-type="table-fn"}   59    10.8   16   2.9    5   0.9[‡](#TF3-3){ref-type="table-fn"}
      Back pain                                                       56                   10.3                     8     1.5    0     0                                     43    7.9    3    0.5    0   0
      Bone pain                                                       50                   9.2                      10    1.8    1     0.2                                   43    7.9    4    0.7    1   0.2
      ALT increased                                                   46                   8.5                      18    3.3    0     0                                     23    4.2    3    0.5    0   0
      Hypokalemia                                                     19                   3.5                      5     0.9    0     0                                     25    4.6    9    1.6    2   0.4
      Hand-foot syndrome                                              1                    0.2                      0     0      0     0                                     246   45.1   79   14.5   0   0

NOTE. If a patient had ≥ two adverse events in the same system organ class or with the same preferred term with different Common Terminology Criteria for Adverse Events grades, the event with the highest grade was used for that patient.

Defined as Standardized Medical Dictionary for Regulatory Activities Queries narrow and broad terms.

Grade 5 events also occurred in four patients (0.7%).

Grade 5 events also occurred in three patients (0.5%).

QoL Analyses
------------

Almost all (\> 95%) QoL data were available at baseline for both arms; completion rates over time decreased similarly in both arms (Data Supplement). GHS/QoL scores were low at baseline in both the eribulin and capecitabine arms (mean ± standard deviation, 56.3 ± 22.2 and 54.7 ± 21.7, respectively). Over time, average GHS/QoL scores improved in both arms, but the linear mixed model and pattern-mixture model showed no significant difference between the groups (linear mixed model: estimated treatment effect, −0.068; *P* = .958; pattern-mixture model: estimated treatment effect, 0.082; *P* = .949).

DISCUSSION
==========

Although eribulin is an active single agent in patients with MBC, it was not superior to capecitabine with regard to either OS or PFS. Our results contrast with those of EMBRACE, in which a statistically significant improvement in OS was seen with eribulin compared with TPC.^[@B18]^ The reasons for this apparent difference are unclear. It is possible that treatment earlier in the course of MBC is less likely to impact OS, as a consequence of such patients typically receiving further lines of cytotoxic or other therapy. Even if therapeutically more active, a first- or second-line regimen may not impact on OS when multiple subsequent lines of effective treatment are administered.

The influence of postprogression therapies on OS is often discussed in studies of MBC, particularly when cross over is imbalanced, and usually in the context of differences in PFS being more apparent than those in OS (which did not occur in our study). In this trial, more patients went on to receive further anticancer treatment after study treatment in the eribulin arm (70.4%) than in the capecitabine arm (62.0%). Specifically, patients in the eribulin arm could cross over and receive capecitabine (49.6%), whereas cross over from capecitabine to eribulin (0.4%) was limited by eribulin only being approved toward the end of the study. Nevertheless, no differences in OS were seen in this study.

The OS data in patients with HER2-negative disease were similar to those reported in EMBRACE,^[@B18]^ and there was no significant difference in PFS between treatment groups in the HER2 subgroups.

Although PFS and OS are similar to other studies in this setting,^[@B7],[@B8]^ ORRs in this study are low. This may be explained, at least in part, by only 88% of patients having disease evaluable for response; the remainder had no baseline scan per independent review (1%), a baseline scan of any type only (7%), or a RECIST response but no confirmatory bone scan (3%).

Eribulin had a manageable tolerability profile, consistent with previous studies; neutropenia, alopecia, leukopenia, and peripheral neuropathy were the most common AEs.^[@B18],[@B24]--[@B27]^ For patients receiving eribulin, the incidences of hematologic and grade 3 or 4 AEs were similar to those in EMBRACE, except for febrile neutropenia. The total incidence of febrile neutropenia with eribulin was lower in this trial (2% with eribulin *v* 0.9% with capecitabine) than in EMBRACE (5%), in which patients had received more prior lines of chemotherapy.^[@B18]^ Neutropenia was managed with dose delays, reductions, and growth factors according to local practice. The use of colony-stimulating factors was higher in the eribulin group than in the capecitabine group (14.6% *v* 3.6%, respectively), consistent with the greater incidence of neutropenia. There were, however, no deaths as a result of neutropenia in either treatment group. AEs experienced with capecitabine, particularly hand-foot syndrome and diarrhea, were also consistent with known AEs.^[@B10],[@B8],[@B28]^ Even though this study used the approved dose of capecitabine (1.25 g/m^2^ twice per day), these AEs were generally within the range observed for capecitabine administered at 1.0 g/m^2^ twice per day,^[@B29]--[@B35]^ a dose commonly used in clinical practice.^[@B36]^ Furthermore, dose-intensity was high for both eribulin and capecitabine in this study. Although incidences of alopecia and peripheral neuropathy were higher for eribulin compared with capecitabine, incidences of diarrhea and vomiting were lower. In summary, the AE profiles of both treatments in this phase III trial were predictable, manageable, and, overall, clinically acceptable. From the patients\' perspective, average GHS/QoL scores generally improved in both treatment arms with no evidence of a difference between treatments.

In conclusion, this trial did not demonstrate superiority of eribulin versus capecitabine for either OS or PFS. The effects on QoL in this population of patients with MBC and the AE profiles of eribulin and capecitabine were consistent with their known AEs.
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HER2/*neu* (human epidermal growth factor receptor 2):

:   also called ErbB2. HER2/neu belongs to the epidermal growth factor receptor (EGFR) family and is overexpressed in several solid tumors. Like EGFR, it is a tyrosine kinase receptor whose activation leads to proliferative signals within the cells. On activation, the human epidermal growth factor family of receptors are known to form homodimers and heterodimers, each with a distinct signaling activity. Because HER2 is the preferred dimerization partner when heterodimers are formed, it is important for signaling through ligands specific for any members of the family. It is typically overexpressed in several epithelial tumors.

overall survival:

:   the duration between random assignment and death.

progression-free survival:

:   time from random assignment until death or first documented relapse, categorized as either locoregional (primary site or regional nodes) failure or distant metastasis or death.
